Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 Safety and Immunogenicity in Adults ≥ 56 Years
NCT04956224Phase 3Completed
- Sponsor
- Valneva
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Viral Vector Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VLA2001 in coronavirus disease 2019 (COVID-19), sponsored by Valneva. Primary endpoints: Frequency and severity of any Adverse Events at Day 43, Geometric Mean Titer of SARS-CoV-2-specific neutralizing antibodies at Day 43 and 1 more. Started Aug 2021; status: completed.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04956224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956224.